SofWave Medical Valuation

Is SOFW.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOFW.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SOFW.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SOFW.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOFW.F?

Key metric: As SOFW.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SOFW.F. This is calculated by dividing SOFW.F's market cap by their current revenue.
What is SOFW.F's PS Ratio?
PS Ratio	2.9x
Sales	US$56.64m
Market Cap	US$162.97m

SOFW.F key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	-53.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SOFW.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SOFW.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.4x
SNWV SANUWAVE Health	6.1x	n/a	US$187.8m
SENS Senseonics Holdings	8.3x	39.0%	US$185.4m
MYO Myomo	6.3x	23.2%	US$157.9m
ZOM Zomedica	4.7x	25.2%	US$125.4m
SOFW.F SofWave Medical	2.9x	n/a	US$591.5m

Price-To-Sales vs Peers: SOFW.F is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (6.5x).

Price to Sales Ratio vs Industry

How does SOFW.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 Companies	Price / Sales	Estimated Growth	Market Cap
INGN Inogen	0.7x	4.2%	US$231.28m
ARAY Accuray	0.5x	5.5%	US$224.26m
NVRO Nevro	0.4x	2.5%	US$172.37m
KEQU Kewaunee Scientific	0.6x	n/a	US$119.84m

50 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SOFW.F is good value based on its Price-To-Sales Ratio (2.9x) compared to the US Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is SOFW.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOFW.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SOFW.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Elevance Health

US$94.4b

Operates as a health benefits company in the United States.

ELV

US$406.96

1.1%

-15.8%

Centene

US$30.3b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.00

-0.6%

-19.9%

Progyny

US$1.3b

A benefits management company, specializes in fertility and family building benefits solutions in the United States.

PGNY

US$15.57

0.8%

-55.0%